225 Symptoms, functional status, and quality of life in patients with controlled and uncontrolled atrial fibrillation. Data from the cross-sectional REALISE-AF registry

Steg, Philippe Gabríel; Alam, Samir; Chiang, Chern‐En; Gamra, Habib; Goethals, Marnix; Inoue, Hiroshi; Krapf, Laura; Lewalter, Thorsten; Merioua, Ihsen; Murı́n, J; Naditch-Brûlé, Lisa; Ponikowski, Piotr; Rosenqvist, Mårten; Silva-Cardoso, José; Zharinov, O.; Brette, Sandrine; O’Neill, Jim

doi:10.1016/s1878-6480(12)70621-3

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Диагностическая картина ФП может варьировать от ощущения сердцебиения, одышки, тяжести в груди, расстройства сна, сонливости, слабости, психосоциальных расстройств до полного отсутствия какой-либо симптоматики [18][19][20][21][22].…”

Section: клиническая картина заболевания или состояния (группы заболеваний или состояний)unclassified

2020 Clinical guidelines for Atrial fibrillation and atrial flutter

Arakelian¹,

Бокерия²,

Васильева³

et al. 2021

Russ J Cardiol

113

View full text Add to dashboard Cite

show abstract

Section: клиническая картина заболевания или состояния (группы заболеваний или состояний)unclassified

2020 Clinical guidelines for Atrial fibrillation and atrial flutter

Arakelian¹,

Бокерия²,

Васильева³

et al. 2021

Russ J Cardiol

113

View full text Add to dashboard Cite

show abstract

“…Ряд авторов объясняют появление кардиальных симптомов «обкрадыванием» коронарного кровообращения при переполнении желудка пищевыми массами: нарушенное кровообращение в сердце уменьшается вследствие перераспределения крови и притока ее к перегруженному желудку [6,9]. Однако это возможно при наличии атеросклеротического изменения в коронарных сосудах.…”

Section: Discussionunclassified

“…Участие К+/Н+-АТФазы в регуляции функции сердца было подтверждено в лабораторных условиях: желудочные изоформы К+/Н+-АТФазы и рецепторы для связывания ИПП присутствуют в клетках сердца млекопитающих. Ученые пришли к заключению, что ИПП могут иметь антиаритмический и кардиопротективный эффекты [9,23].…”

Section: Discussionunclassified

Rare variant of Remkheld syndrome

Chepurnenko

Nasytko

Shavkuta

2022

jour

View full text Add to dashboard Cite

Introduction. Gastroesophageal reflux disease (GERD) can be accompanied by a triad of cardiac symptoms (arrhythmia, cardialgia, signs of autonomic dysfunction). This syndrome is called gastro-cardiac or Remheld syndrome. The most common rhythm disturbances in Remheld syndrome are atrial fibrillation, supraventricular extrasystole. In the clinical case we have described, a rare variant of Remheld’s syndrome is presented: paroxysmal ventricular tachycardia with GERD.Description of the clinical case. Patient V., 48 years old, applied to a cardiologist on 21.04.21 with complaints of attacks of sudden palpitations, disturbing for six months. From the anamnesis it is known that since 2017 he has been suffering from GERD, he does not take drugs for stopping reflux attacks for 6 months, canceling it on his own. According to Holter ECG monitoring from 03/20/21, paroxysmal ventricular tachycardia was revealed. According to echocardioscopy data from 04/26/21, no structural changes that could be the cause of this life-threatening rhythm disturbance were found. Video gastroscopy from 04/28/21: distal reflux esophagitis. Endoscopic signs of hiatal hernia. Lack of cardia 2 tbsp. Gastroesophageal prolapse. At the consultation with a gastroenterologist, the patient was prescribed both non-drug (lifestyle correction) and drug treatment: rabeprozole, clarithromycin, amoxicillin and others. In addition for the relief of paroxysmal ventricular tachycardia—amiodarone, telmisartan.Discussion. According to studies, one of the mechanisms of arrhythmia in GERD is associated with the excitation of the distal esophagus by refluctate with the development of viscero-visceral reflexes mediated through n. vagus. Increased activation of n. vagus creates an arrhythmogenic substrate for the re-entry mechanism, and thus increases the risk of arrhythmias. Antiarrhythmic therapy along with the treatment of GERD led to the elimination of VT paroxysms. Later, 2 months after the withdrawal of antiarrhythmic drugs against the background of ongoing GERD therapy, paroxysms of VT were not recorded. This was also a confirmation of the pathogenetic relationship between GERD and paroxysmal VT.Conclusion. The case is of interest to the development of a life-threatening rhythm disturbance: paroxysmal ventricular tachycardia against the background of GERD, which is a very rare variant of Remkheld’s syndrome and is not found in the available literature.

show abstract

“…Although therapeutically convenient and often well‐tolerated, rate control does not halt the progression of adverse electrical and structural remodeling in AF. Restoring sinus rhythm in patients with AF could offer an advantage in regard to quality of life; however, the currently available antiarrhythmics are limited in their efficacy . Until the results of the landmark Atrial Fibrillation Follow‐up Investigation of Rhythm Management (AFFIRM) trial, medical rhythm control was believed by many to be a superior therapy for the management of AF.…”

Section: Introductionmentioning

confidence: 99%

“…Restoring sinus rhythm in patients with AF could offer an advantage in regard to quality of life; however, the currently available antiarrhythmics are limited in their efficacy. 6,7 Until the results of the landmark Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, medical rhythm control was believed by many to be a superior therapy for the management of AF. Results from the AFFIRM trial and the subsequent Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study which also demonstrated noninferiority of rate control are reflected in the AF consensus guidelines recommendation for the use of rate control as a reasonable first-line approach for many patients with AF.…”

mentioning

confidence: 99%

Impact of treatment crossovers on clinical outcomes in the rate and rhythm control strategies for atrial fibrillation: Insights from the AFFIRM (Atrial Fibrillation Follow‐up Investigation of Rhythm Management) trial

Maan

Zhang

Qin

et al. 2017

Pacing Clinical Electrophis

View full text Add to dashboard Cite

We investigated the rates and reasons for crossover to alternative treatment strategies and its impact on mortality in patients who were enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. Over a mean follow-up period of 3.5 years, 842 patients underwent crossover to the alternative treatment arms in AFFIRM. The rate of crossover from rhythm to rate control (594/2,033, 29.2%) was more frequent than the rate of crossover from rate to rhythm control (248/2,027, 12.2%, P < 0.0001). The leading reasons for crossover from rhythm to rate control were failure to achieve or maintain sinus rhythm (272/594, 45.8%) and intolerable adverse effects (122/594, 20.5%). In comparison, the major reasons for crossover from rate to rhythm control were failure to control atrial fibrillation symptoms (159/248, 64.1%) and intolerable adverse effects (9/248, 3.6%). This difference in crossover pattern was statistically significant (P < 0.0001). There was a significantly decreased risk of all-cause mortality (adjusted HR: 0.61, 95% CI: 0.48-0.78, P < 0.0001) and cardiac mortality (adjusted hazard ratio [HR]: 0.61, 95% confidence interval [CI]: 0.43-0.88, P = 0.008) in the subgroup of patients who crossed over from rhythm to rate control as compared to those who continued in rhythm control. There was a nonsignificant trend toward decreased all-cause (adjusted HR: 0.76, 95% CI: 0.53-1.10, P = 0.14) and cardiac mortality (adjusted HR: 0.70, 95% CI: 0.42-1.18, P = 0.18) in patients who crossed over from rate to rhythm control as compared to those who continued rate control.

show abstract

225 Symptoms, functional status, and quality of life in patients with controlled and uncontrolled atrial fibrillation. Data from the cross-sectional REALISE-AF registry

Cited by 4 publications

References 0 publications

2020 Clinical guidelines for Atrial fibrillation and atrial flutter

2020 Clinical guidelines for Atrial fibrillation and atrial flutter

Rare variant of Remkheld syndrome

Impact of treatment crossovers on clinical outcomes in the rate and rhythm control strategies for atrial fibrillation: Insights from the AFFIRM (Atrial Fibrillation Follow‐up Investigation of Rhythm Management) trial

Contact Info

Product

Resources

About